Newsroom


Please note that the Company does not update, correct or revise news releases after they have been issued. For the most current information about the Company, please refer to the most recent releases.
10

Bausch + Lomb Introduces ORBSCAN®3 Anterior Segment Analyzer


New Enhancements – Driven by 20 Years of Field Use, Research – Poised to Benefit Expanding Field of Refractive Surgery

FOR RELEASE MONDAY, OCTOBER 10, 2016

 

BRIDGEWATER, NJ – Bausch + Lomb, a leading global eye health company, today introduced the ORBSCAN®3 anterior segment analyzer, the third generation of the multidimensional ORBSCAN topographer. The new platform, which features multiple enhancements driven by more than 20 years of field use and research, is designed to serve as an indispensable screening tool to the increasing number of ophthalmic surgeons performing new refractive procedures.

 

“Since Bausch + Lomb acquired the ORBSCAN technology in 1999, we’ve learned a great deal from its use in the field and in countless studies involving patients pre- and post-LASIK, RK, CK and LTK,” said Chuck Hess, vice president and general manager, U.S. Surgical, Bausch + Lomb. “The data points and experience we’ve garnered helped inform the development of the ORBSCAN3, and we will continue investing in this technology to meet surgeons’ ever evolving needs as part of our commitment to innovation and education.”

 

The ORBSCAN3 offers surgeons the ability to examine anterior and posterior astigmatism and optical pachymetry, providing data points on corneal biomechanics and stability that can inform surgical choices and identify appropriate candidates for all of these procedures.  ORBSCAN3 gives an accurate assessment of the size, shape and extent of surface power abnormalities, thus enabling the surgeon to provide high quality refractive care.

“Prescreening is a critical step to ensuring optimal patient selection and outcomes in refractive surgery,” said Michael Endl, M.D., Fichte Endl & Elmer EyeCare in Buffalo, New York.  “Cited in hundreds of peer-reviewed published clinical studies, the ORBSCAN II and ORBSCAN IIz have been invaluable resources in my practice for many years, and I fully expect the ORBSCAN3 to expand on this history of excellence.”

The ORBSCAN3 provides a complete contact-free analysis of the eye’s anterior segment by utilizing slit scanning technology with an advanced Placido disc system. The ORBSCAN3 also features user-friendly touch screen technology and completely new software, and is able to analyze elevation and curvature measurements on both the anterior and posterior surfaces of the cornea, full corneal pachymetry, white-to-white measurement, and anterior chamber depth and angle kappa. 

The ORBSCAN3 will be available for surgeons to test at the Bausch + Lomb booth (#3026) at the American Academy of Ophthalmology (AAO) in Chicago, October 15-18, 2016.

 

About Bausch + Lomb
Bausch + Lomb, a Valeant Pharmaceuticals International, Inc. company, is a leading global eye health organization that is solely focused on protecting, enhancing and restoring people’s eyesight. Its core businesses include over-the-counter supplements, eye care products, ophthalmic pharmaceuticals, contact lenses, lens care products, ophthalmic surgical devices and instruments. Bausch + Lomb develops, manufactures and markets one of the most comprehensive product portfolios in the industry, which is available in more than 100 countries.

 

Orbscan is a trademark of Bausch & Lomb Incorporated or its affiliates.
© 2016 Bausch & Lomb Incorporated. OR3.0014.USA.16

 


News Media Contacts:
Kristy Marks

Sr. Manager, Communications, Bausch + Lomb

(908) 927-0683 or kristy.marks@bausch.com

Teresa Panas
BioComm Network, on behalf of Bausch + Lomb
(973) 809-8590 or tpanas@biocommnetwork.com
Actions: E-mail | Permalink |